Quantum BioPharma Cuts Cash Burn 44%, Extends Runway to October 2027
QNTM sits 68% above its 52-week low of $2.07.
Summary
Quantum BioPharma reported Q2 2026 results showing a 53% year-over-year reduction in operating expenses to $2.29 million and a 44% drop in cash used in operations to $3.46 million for the first half. Combined cash and digital assets rose to $9.5 million from $4.1 million at year-end, extending the cash runway to at least October 2027. The company also reiterated the FDA's August 10 clearance of its Lucid-MS IND for a Phase 2 trial in progressive multiple sclerosis. The improved liquidity and cost discipline materially reduce near-term dilution risk for a micro-cap biotech. The Phase 2 trial initiation timeline remains the key clinical catalyst.
At the time of this announcement, QNTM was trading at $3.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.7M. The 52-week trading range was $2.07 to $25.30. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.